Seelos Therapeutics, Inc.
SEELQ
$0.0005
$0.000.00%
OTC PK
| 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | 06/30/2023 | |
|---|---|---|---|---|---|
| Revenue | 76.05% | 144.31% | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 76.05% | 144.31% | -- | -- | -- |
| Cost of Revenue | -52.57% | -49.32% | -49.39% | 155.70% | 155.70% |
| Gross Profit | 54.64% | 51.23% | 51.92% | -150.23% | -151.67% |
| SG&A Expenses | -7.12% | -6.02% | 2.35% | -27.52% | -27.60% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -43.87% | -40.59% | -39.79% | -34.66% | -22.90% |
| Operating Income | 46.34% | 42.86% | 42.89% | 36.59% | 24.45% |
| Income Before Tax | 105.04% | 62.84% | 48.48% | 37.80% | -10.69% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 105.04% | 62.84% | 48.48% | 37.80% | -10.69% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 105.04% | 62.84% | 48.48% | 37.80% | -10.69% |
| EBIT | 46.34% | 42.86% | 42.89% | 36.59% | 24.45% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 106.76% | 73.58% | 57.81% | 43.63% | 0.11% |
| Normalized Basic EPS | 113.58% | 85.86% | 68.39% | 53.10% | 10.10% |
| EPS Diluted | 78.85% | 45.06% | 29.84% | 18.84% | 0.10% |
| Normalized Diluted EPS | 112.06% | 84.40% | 66.95% | 51.85% | 10.10% |
| Average Basic Shares Outstanding | 191.21% | 100.12% | 38.15% | 15.37% | 9.71% |
| Average Diluted Shares Outstanding | 194.47% | 103.08% | 41.16% | 18.40% | 9.71% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |